TScan Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data and issuance costs)
| Additional · Accumulated · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Voting Common Stock · Non-voting Common Stock · Paid-In · Other Comprehensive · Accumulated · Stockholders’ | |||||||||
| Shares · Amount · Shares · Amount · Capital · Income · Deficit · Equity | |||||||||
| Balances at January 1, 2024 | 43,552,941 | $4 | 4,276,588 | $1 | $398,459 | $ | - | $(247,597) | $150,867 |
| Exercise of stock options | 586,081 | - | - | - | 1,717 | - | - | 1,717 | |
| Issuance of common stock under employee stock purchase plan | 82,153 | - | - | - | 333 | - | - | 333 | |
| Issuance of common stock, net of offering costs | 4,958,068 | 1 | - | - | 33,130 | - | - | 33,131 | |
| Issuance of pre-funded warrants, net of offering costs | - | - | - | - | 158,071 | - | - | 158,071 | |
| Conversion of convertible debt | 3,134,796 | - | - | - | 14,750 | - | - | 14,750 | |
| Stock-based compensation expense | - | - | - | - | 9,549 | - | - | 9,549 | |
| Net loss | - | - | - | - | - | - | (127,499) | (127,499) | |
| Unrealized gain on available-for-sale securities | - | - | - | - | - | 51 | - | 51 | |
| Balances at December 31, 2024 | 52,314,039 | $5 | 4,276,588 | $1 | $616,009 | $51 | $(375,096) | $240,970 | |
| Issuance of common stock under employee stock purchase plan | 234,826 | - | - | - | 264 | - | - | 264 | |
| Issuance of common stock upon exercise of pre-funded warrants | 76,170 | - | - | - | - | - | - | - | |
| Stock-based compensation expense | - | - | - | - | 11,706 | - | - | 11,706 | |
| Net loss | - | - | - | - | - | - | (129,766) | (129,766) | |
| Unrealized loss on available-for-sale securities | - | - | - | - | - | (51) | - | (51) | |
| Balances at December 31, 2025 | 52,625,035 | $5 | 4,276,588 | $1 | $627,979 | $ | - | $(504,862) | $123,123 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.